- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06316310
Effect of Acupoint Thread Embedding on Obesity
The Effect and Safety of Acupoint Thread Embedding on Over-weight and Obesity Treatment : A Randomized, Single-Blind, Sham- Controlled Study
Study Overview
Detailed Description
Obesity refers to a complex chronic disease in which there is excessive accumulation of body fat. As of 2016, there were more than 650 million obese people worldwide, and it is expected to reach 1.12 billion by 2030, with at least 2.8 million deaths due to obesity each year, according to surveys. In Europe, 60 percent of the population is already overweight or obese. The incidence of obesity is also increasing rapidly in China, with a recent report by The Lancet showing that the number of obese people in China has reached 85 million, making it the country with the highest number of obese people in the world. In 2002, the China Obesity Task Force recommended threshold value to define overweight as Body Mass Index (BMI) of ≥ 24 kg/m2, a waist circumference (WC) ≥of 85 cm for men and a WC ≥ 80 cm for women, or a Waist-to-Hip Ratio (WHR) of ≥ 0.9 for men and a WHR ≥ 0.8 for women, and to define obesity as a BMI ≥ 28 kg/m2. Studies have shown that Asian populations have higher health risks at the same BMI and WC levels due to the distribution of adipose tissue. Acupoint thread embedding is a widely recognized therapy to lose weight in clinical practice.But there are some doubts about the effectiveness of acupoint thread embedding versus sham acupoint thread embedding in treating obesity due to its lack of medical evidence.
This randomized placebo-controlled clinical trial is aimed to investigate the effect and safety of acupoint thread embedding (ATE) in obese patients. The investigators designed a protocol for a randomized controlled trial, in which 110 eligible patients will be randomly assigned to one of the two groups: the ATE group (receiving ATE treatment with health education) and the sham acupoint thread embedding (SATE) group (receiving SATE treatment with health education). A total of 6 sessions of interventions will be given for consecutive 12 weeks, followed by 12 weeks follow-up period. Each session of ATE or SATE treatment will last for about 30 minutes. The primary outcome is the change of the body mass index (BMI) at week 12. The secondary outcomes include the change of patient's body weight and body circumference, results from the blood tests (FBG, LDL-C, HDL-C, TG and TC), the abdominal visceral fat tissue thickness scanned by abdominal B-ultrasound, data collected from the body composition analyzer, the and scores of the impact of weight on quality of life (IWQOL-Lite), the well-being index (WHO-5), visual analog scale (VAS) of appetite and hamilton anxiety scale(HAMA). All adverse effects will be accessed by the treatment emergent symptom scale (TESS) from baseline to the follow-up period. The body weight and circumferences and BMI will be calculated at baseline, week 6, week 12, and week 24. The IWQOL-Lite, WHO-5, VAS, the HAMA, blood tests and abdominal B-ultrasound will be calculated at baseline and week 12. All patients will be provided with the same health education brochure to choose more beneficial personalized lifestyle during the 12-week intervention period.
All analyses will be performed on the intention-to-treat (ITT) population of participants who have at least one treatment. Missing data will be handled using the multiple imputation method, on the assumption that values at each time point follow a specific distribution calculated by the computer software R V.3.5. The primary outcome is the change of the body mass index (BMI) at week 12. Linear mixed effects models will be used for analyses with the use of the statistical software SPSS V.20.0. The t-test will be used to compare the measurement data between either two groups from the baseline to follow-up; the rank sum test will be used for ranked data while the Chi-squared test will be used to analyze categorical data. The significance level that will be used for statistical analysis with 2-tailed testing will be 2.5%. Data values will mainly be presented as Mean±SD. The findings from this trial will help further explore the efficacy and safety of ATE on losing weight for patients with obesity, as well as determine the differences between the ATE and SATE treatment.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200071
- Recruiting
- Shanghai Municipal Hospital of Traditional Chinese Medicine
-
Contact:
- Shifen Xu, PhD
- Phone Number: +8613761931393
- Email: xu_teacher2006@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Females aged 18~45 years old;
- BMI≥24.0 kg/m2;
- WC≥80cm ; recommended BMI and WC threshold value to define overweight in China;
- Stable weight change (increase or decrease of ≤4 kg) within 3 months prior to the start of the test;
- Agree to participate in the trial and sign a written informed consent form;
Exclusion Criteria:
- Secondary obesity caused by drugs, or neuro-endocrine-metabolic disorders (such as thalamic disease, hypopituitarism, etc.);
- History of bariatric surgery (gastric reduction, liposuction, etc.);
- Are taking medications that may affect the results of the trial (weight):
- Severe ulcers, abscesses, skin infections, etc. at the acupuncture site;
- Severe heart, brain, lung, liver and kidney insufficiency, hematopoietic system disease or other serious diseases;
- Participated in other clinical medical trial studies in the past 1 month;
- History of acupoint thread embedding in the past 6 months;
- Alcoholism, drug abuse, or smoking (change in smoking habits within the past 2 months or a plan to quit smoking during the study period);
- Pregnant and lactating women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Acupoint Thread Embedding group+health education
Acupuncture thread embedding (ATE), extension and development of acupuncture therapy, which emerged in mid 1950s, is an acupoint stimulation technique which sterile biodegradable threads (such as polydioxanone (PDO) threads) are inserted into acupuncture points, by using hollow core embedding needles.
The aim of this therapy is provide long term stimulation of acupoints, making this technique one of the most commonly used methods for treating obesity.
|
Acupoint embedding therapy:Main acupoints: Shangguan (CV-13), Xiaguan (CV-10), Tianshu (ST-25), Daheng (SP-15), Fenglong (ST-40), Qihai (CV-6), Zhongguan (CV-12), Zusanli (ST-36), Quchi (LI-11), Guanyuan (CV-4), Wailing (ST-26), Daju (ST-27), Shuidao (ST-28), Daimai (GB-26), Liangmen (ST-21), Ashi acupoints , where local fat accumulation in the abdomen.
Methods of operation: With the patient in the prone position and all acupoints routinely sterilized, the acupuncturist will use sterile forceps to insert a 3-0 × 2-cm poly-p-dimethyl-hydroxy-oxazolone (PDO) thread into the tip of the #6 (0.6 mm × 60 mm) disposable embedded thread needle.
The tissue around the area of the acupuncture point will be lifted with the thumb and forefinger of the non-dominant hand and the needle will be inserted into the acupuncture point to a depth of 1.5 cm with the dominant hand.
Each treatment will last maximum of 10 minutes and the intervention will be repeated every 2 weeks for a total of 6 sessions.
Other Names:
|
Sham Comparator: Sham Acupoint Thread Embedding group+health education
Sham acupoint thread embedding method in this study is set as the Sham acupoint thread embedding manipulated at the same main acupoints won't be put into trocar and de qi sensation will not be obtained. The aim of the sham acupoint thread embedding is to eliminate the possible placebo effect of ATE treatment. |
Acupoint embedding therapy:Main acupoints: Shangguan (CV-13), Xiaguan (CV-10), Tianshu (ST-25), Daheng (SP-15), Fenglong (ST-40), Qihai (CV-6), Zhongguan (CV-12), Zusanli (ST-36), Quchi (LI-11), Guanyuan (CV-4), Wailing (ST-26), Daju (ST-27), Shuidao (ST-28), Daimai (GB-26), Liangmen (ST-21), Ashi acupoints , where local fat accumulation in the abdomen.
Methods of operation: With the patient in the prone position and all acupoints routinely sterilized, the acupuncturist will use sterile forceps to insert a 3-0 × 2-cm poly-p-dimethyl-hydroxy-oxazolone (PDO) thread into the tip of the #6 (0.6 mm × 60 mm) disposable embedded thread needle.
The tissue around the area of the acupuncture point will be lifted with the thumb and forefinger of the non-dominant hand and the needle will be inserted into the acupuncture point to a depth of 1.5 cm with the dominant hand.
Each treatment will last maximum of 10 minutes and the intervention will be repeated every 2 weeks for a total of 6 sessions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body Mass Index (BMI)
Time Frame: week0, week6, week12, week24
|
one of the criteria for evaluating the body weight and health status of a person.
BMI = weight (kg)/height (m)2.
Each subject will be provided with a free Bluetooth Internet-enabled scale to monitor their weight at regular intervals, and the researcher will be able to access the data from the backend
|
week0, week6, week12, week24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in body weight
Time Frame: week0, week6, week12, week24
|
The change in body weight at the end of the intervention compared to the baseline.
|
week0, week6, week12, week24
|
Changes in body circumference
Time Frame: week0, week6, week12, week24
|
Waist circumference (WC), hip circumference (HC), waist-hip ratio (WHR), waist-height ratio (WHtR), and the average value of the changes in each circumference at the end of the intervention were calculated compared with the baseline.
WHR=WC/HC; WHtR=WC/height .
|
week0, week6, week12, week24
|
Body composition analysis
Time Frame: week0, week6, week12, week24
|
Evaluating changes in body fat percentage or composition by using bioelectrical impedance analysis (BIA) device (InBody770; Biospace, Seoul, Korea)., which allows for high-density body composition measurements, including muscle mass, body water content, body fat percentage, visceral fat grade, and other body components, by bioelectrical impedance analysis.
|
week0, week6, week12, week24
|
Abdominal visceral fat tissue thickness
Time Frame: week0, week12
|
Abdominal B-ultrasound scanning of the upper abdomen and flat umbilicus level will be used to quantitatively calculate the visceral fat thickness.
|
week0, week12
|
Fasting blood glucose (FPG)
Time Frame: week0, week12
|
glucose concentration in the blood in the early morning fasting, which can reflect the function of pancreatic β-cells,HOMA-IR, Insulin level.
|
week0, week12
|
Blood lipid profile
Time Frame: week0, week12
|
including Low-density Lipoprotein (LDL), High density lipoprotein (HDL), triglyceride (TG), cholesterol (TC), reflects the lipid metabolism within the body.
|
week0, week12
|
Impact of Weight on Quality-of-Life Scale (IWQOL-Lite)
Time Frame: week0, week12
|
a 31-item self-report scale consisting of a total score and individual scores on 5 dimensions, i.e., physical functioning, self-esteem, sexuality, public stress, and work, to assess the quality of life of obese patients
|
week0, week12
|
Well-Being Index (WHO-5)
Time Frame: week0, week12
|
shot, self-administered subjective measure of well-being over the last two weeks.
It consists of 5 positively worded item that is rated on 0-6 which is 0 means at no time and 5 is all the time.
|
week0, week12
|
Visual analog scale (VAS) of appetite
Time Frame: week0, week12
|
This method relies on a line segment of 100 mm or 150mm in length, with the two ends pointing to "I have no appetite at all" and "I have a very good appetite" respectively.
Subjects mark the line according to their level of appetite.
The patient was determined to have a reduced appetite if the measured line segment was <50 mm or 70 mm.
|
week0, week12
|
Hamilton Anxiety Scale (HAMA)
Time Frame: week0, week12
|
The CCMD-3 Chinese Diagnostic Criteria for Mental Disorders lists it as an important diagnostic tool for anxiety disorders, and is often used clinically as the basis for the diagnosis and degree classification of anxiety disorders.
The total score can better reflect the severity of anxiety symptoms, and can be used to evaluate the severity of anxiety symptoms in patients with anxiety and depressive disorders and evaluate the effects of various drugs and psychological interventions.
According to the information provided by the Chinese scale collaboration group: the total score is ≥ 29 points, which may be severe anxiety; ≥ 21 points, there must be significant anxiety; ≥ 14 points, there is definitely anxiety; More than 7 points, there may be anxiety; If the score is less than 7, there are no anxiety symptoms.
|
week0, week12
|
Adverse effects
Time Frame: week6, week12, week24
|
Any adverse event (described as unfavourable or unintended signs, symptoms or diseases occurring during the trial) related to the intervention will be reported by patients and practitioners and accessed by the Treatment Emergent Symptom Scale (TESS) which is used as an associated indicator to mainly evaluate the safety of acupoint thread embedding treatment in this trial.
|
week6, week12, week24
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XSF20240312
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on acupoint thread embedding
-
Shanghai University of Traditional Chinese MedicineUnknownWeight Loss | Simple ObesityChina
-
Indonesia UniversityCompletedMyofascial Pain of Upper Trapezius MuscleIndonesia
-
Kyunghee University Medical CenterKyung Hee University Hospital at Gangdong; DongGuk University; Daegu Korean Medicine...CompletedLumbar Disc HerniationKorea, Republic of
-
University of Medicine and Pharmacy at Ho Chi Minh...CompletedOverweight or ObesityVietnam
-
Indonesia UniversityCompletedWrinkle | Aging ProblemsIndonesia
-
Taipei City HospitalNational Yang Ming UniversityUnknown
-
Indonesia UniversityCompletedQuality of Life | Post Operative Pain, Acute | Renal Transplant Donor of Left Kidney | Acupuncture AnalgesiaIndonesia
-
The First Affiliated Hospital of Soochow UniversityRecruitingTraditional Chinese MedicineChina
-
University of Medicine and Pharmacy at Ho Chi Minh...Completed
-
University of Medicine and Pharmacy at Ho Chi Minh...RecruitingEpilepsy, Drug Resistant | Acupuncture TherapyVietnam